Efficacy and safety of artesunate for patients with IgA nephropathy: a study protocol for a multicenter, double-blind, randomized, placebo-controlled trial
Qi Chen(Macau University of Science and Technology), Jingwei Zhou(Xuzhou Medical College), Yanhong Huo(Chinese PLA General Hospital), Cun Shen(Capital Medical University), Zhenjie Chen(Nanjing University of Information Science and Technology), Zi Wang(Sichuan University), Lijun Liu(Peking University), Hang Li(University of Hong Kong - Shenzhen Hospital), Shichao Li(Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine), Yingbo Guo(Beijing University of Chinese Medicine), Weiwei Sun(Ningbo University), Jicheng Lv(Ministry of Education of the People's Republic of China)
Cited by 7
Related Papers
Worldwide access to treatment for end-stage kidney disease: a systematic review
|The Lancet|2015|2.3k
Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group
|Kidney International|2017|1.2k
Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis
|The Lancet|2015|984